How Central Imaging Enhances Endpoint Quality in Multicenter Clinical Studies

In multicenter clinical trials, imaging endpoints are vulnerable to inter-site and inter-reader variability. Central imaging addresses this by standardizing acquisition through an imaging charter and routing images to trained, independent central readers, producing consistent, reproducible endpoint data that strengthens statistical power and regulatory confidence.

Give the same CT scan to two experienced radiologists and ask them to identify target lesions and measure them. The two answers will not be identical. Neither radiologist is wrong. They selected different lesions, drew the caliper slightly differently, and made different judgment calls about a borderline node.

Now scale that to sixty sites, four countries and eighteen months of follow-up. The measurement noise the trial has to absorb is no longer a rounding issue. In a multicenter study, the largest source of variation in an imaging endpoint is frequently not the drug.

The Multicenter Variability Problem

Variability enters the dataset through two independent doors, and confusing them leads to the wrong fix.

Inter-site variability is about acquisition. Scanner make and model, slice thickness, reconstruction kernel, contrast agent and injection timing, field of view, patient positioning, breath-hold instruction. A lesion measured on a 5 mm slice and the same lesion measured on a 1 mm slice are not the same measurement.

Inter-reader variability is about interpretation. Which lesions qualify as measurable, which five to select as targets, where exactly the boundary of a lesion sits, whether a new finding is a new lesion or an artifact, and how to treat a node that has shrunk to the threshold.

Standardizing acquisition does nothing about reader disagreement. Centralizing reads does nothing about a site that scanned at the wrong slice thickness. Endpoint quality requires both, and the two are managed through different instruments.

How Centralization Reduces Variability

Standardized acquisition and the imaging charter

The imaging charter is the document that constrains acquisition before it happens. FDA guidance on clinical trial imaging endpoint process standards describes it as a single document or series of documents detailing the trial's imaging methodology inluding clinical trials provisioning, and expects it to describe how potential sources of imaging bias and variability are controlled.

In practice it specifies the equipment technical settings to be used at each site and identifies which deviations from those settings are acceptable. It covers patient preparation and positioning, the timepoint windows, the reading methodology, the read design, reader qualification and the archiving path. Sites are then qualified against it, which the guidance suggests can involve phantom imaging, on-site inspection or training.

A charter written after enrollment starts is a description. Written before, it is a control.

Independent central reads

Central reading replaces sixty local interpretations with one convention applied by a managed panel. Readers are blinded to treatment assignment, and the guidance recommends blinding to individual-level clinical data as well, so that a reader cannot infer allocation from the narrative.

Read design matters as much as reader quality. A single-read design is fastest and carries the reader's individual bias into the endpoint. A double read with adjudication, where two readers work independently and a third resolves discordance, costs more and produces a result that is reproducible by construction. In studies where progression drives the primary endpoint, that difference is usually worth paying for.

Reader training and quality control

Consistency between readers is manufactured, not selected for. The guidance expects reader training documentation covering the imaging-specific aspects of interpretation, including training manuals and training images, and it recommends prespecified performance criteria for reader qualification.

It also recommends something that is easy to skip: periodic blinded testing during the trial, using predefined image sets interspersed with real trial images, to verify that readers remain consistent over time. Reader drift across an eighteen-month study is a real phenomenon, and it is invisible unless someone measures it.

Impact on Endpoint Reliability and Statistical Power

The statistical argument is straightforward. Measurement error inflates the variance of the endpoint. Inflated variance widens confidence intervals and reduces the power to detect a treatment effect of a given size. Reducing measurement noise is arithmetically equivalent to enrolling more patients, without enrolling more patients.

The evidence on how much this matters is more nuanced than vendor material usually admits, and it is worth stating accurately. A meta-analysis by Amit and colleagues, published in the European Journal of Cancer in 2011, compared local evaluation with blinded independent central review of progression across oncology trials and found a strong correlation between the two estimates of treatment effect, with a correlation coefficient of 0.947. The authors concluded that local evaluation provides a reliable estimate with little evidence of systematic evaluation bias, and suggested that a sample-based audit approach may be sufficient in many cases.

That finding does not undermine the case for central imaging. It sharpens it. Random reader disagreement tends to cancel out across arms in a well-blinded randomized trial. Systematic bias does not, and neither does acquisition variation that affects one region or one period of enrollment more than another. The value of centralization concentrates where bias can be directional: open-label designs, subjective endpoints, single-arm studies where there is no comparator to cancel anything out, and small trials where a handful of misclassified events moves the result.

When Central Reading Is Worth It

The honest decision rule has four inputs.

• Blinding. If the trial is open-label, or if treatment allocation can be inferred from imaging or clinical data, central blinded reading is doing work nothing else can do.

• Subjectivity of the measurement. Quantitative measures that are widely performed and low in variability need it less. FDA guidance states directly that centralized interpretation is not always critical, even for a Phase III trial, in those conditions.

• Study design. Single-arm studies have no randomization to cancel out reader noise. Registration studies carry a level of scrutiny that documentation has to match.

• Trial size and effect size. A small study with a modest expected effect has no tolerance for measurement noise. A large study with a strong effect has more.

Where several of these point the same way, the case is clear. Where they do not, a sample-based central audit of local reads is a defensible middle position, and saying so builds more credibility than claiming every study needs a full central read.

Banook manages reader consistency as an ongoing process rather than a qualification step. The panel runs to more than 500 board-certified specialists worldwide, each with at least ten years of experience, spanning radiology, oncology, neuroradiology, nuclear medicine, dermatology and cardiology, which makes it possible to match reader specialty to the criteria a protocol actually uses. Quality assurance combines statistical monitoring of reader performance, consensus sessions, retraining where performance drifts, and phantom-based bias checks. Each study is governed by an imaging manual covering site qualification and acquisition, and an imaging review charter covering the independent central read procedure, reader management, reading methodology and schedule. The group has supported more than 350 imaging studies, including pivotal trials.

The strategic case for central imaging is covered in Why Central Imaging Has Become a Strategic Asset in Clinical Trial Execution

👉 Discover Banook Central Imaging solutions or contact our team of imaging experts

Frequently Asked Questions

Why do imaging endpoints vary between sites?

Because acquisition is not identical. Scanner models, slice thickness, reconstruction settings, contrast timing, field of view and patient positioning all differ between sites and all affect the measurement. Local reading practice adds a second layer of variation on top of the first.

What is an imaging charter?

The imaging charter is the document that defines a trial's imaging methodology: equipment settings and acceptable deviations, patient preparation, timepoint windows, the read design, reader qualification, the reading methodology, adjudication rules and archiving. FDA guidance expects it to describe how sources of imaging bias and variability are controlled.

What is inter-reader variability?

Inter-reader variability is the difference in results when two qualified readers interpret the same images: different target lesion selection, different measurement boundaries, different judgment on borderline findings. It is managed through a single reading convention, documented reader training, prespecified qualification criteria and periodic blinded re-testing.

How does central imaging improve data quality?

By constraining acquisition in advance through the imaging charter, detecting deviations at quality control while the visit window is still open, and replacing site-by-site interpretation with one documented convention applied by a monitored reader panel. The result is measurement error that is consistent rather than variable, which is what statistical analysis can accommodate.

Does every multicenter trial need central reads?

No. FDA guidance states that centralized interpretation is not always critical, even for a Phase III trial, when the measurement is quantitative, widely performed and low in variability. Published meta-analysis has also found strong agreement between local evaluation and central review of progression in well-blinded randomized oncology trials. The case is strongest in open-label designs, single-arm studies, subjective endpoints and smaller trials.